Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

DR, Spigel; C, Faivre-Finn; JE, Gray; D, Vicente; D, Planchard; L, Paz-Ares; JF, Vansteenkiste; MC, Garassino; R, Hui; X, Quantin; A, Rimner; YL, Wu; M, Özgüroğlu; KH, Lee; T, Kato; Wit M, de; T, Kurata; M, Reck; BC, Cho; S, Senan; J, Naidoo; H, Mann; M, Newton; P, Thiyagarajah; SJ, Antonia

doi:10.1200/jco.21.01308

Public

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Feb 2, 2022

Authors:

Spigel DR

Faivre-Finn C

Gray JE

Abstract

<h4>Purpose</h4>The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end poi...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!